PL2825542T3 - Modulatory wątrobowego receptora x - Google Patents

Modulatory wątrobowego receptora x

Info

Publication number: PL2825542T3
Authority: PL; Poland
Prior art keywords: liver; receptor modulators; modulators; receptor
Prior art date: 2012-03-16

Application number

PL13712103T

Other languages

English (en)

Inventor

Chengguo Dong

Yi Fan

Katerina Leftheris

Stephen Lotesta

Suresh B. Singh

Colin Tice

Wei Zhao

Yajun Zheng

Linghang Zhuang

Original Assignee

Vitae Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-16

Filing date

2013-03-14

Publication date

2017-05-31

2013-03-14 Application filed by Vitae Pharmaceuticals, Inc. filed Critical Vitae Pharmaceuticals, Inc.

2017-05-31 Publication of PL2825542T3 publication Critical patent/PL2825542T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)

PL13712103T 2012-03-16 2013-03-14 Modulatory wątrobowego receptora x PL2825542T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261612063P	2012-03-16	2012-03-16

Publications (1)

Publication Number	Publication Date
PL2825542T3 true PL2825542T3 (pl)	2017-05-31

Family

ID=47997958

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13712103T PL2825542T3 (pl)	2012-03-16	2013-03-14	Modulatory wątrobowego receptora x

Country Status (28)

Country	Link
US (5)	US9073931B2 (pl)
EP (1)	EP2825542B1 (pl)
JP (3)	JP6114815B2 (pl)
KR (1)	KR102069913B1 (pl)
CN (1)	CN104203950B (pl)
AU (1)	AU2013232069B2 (pl)
BR (1)	BR112014022780A8 (pl)
CA (1)	CA2865639C (pl)
CY (1)	CY1118323T1 (pl)
DK (1)	DK2825542T3 (pl)
EA (1)	EA026431B1 (pl)
ES (1)	ES2607113T3 (pl)
HK (1)	HK1206332A1 (pl)
HR (1)	HRP20161690T1 (pl)
HU (1)	HUE030785T2 (pl)
IL (2)	IL234301A (pl)
LT (1)	LT2825542T (pl)
ME (1)	ME02660B (pl)
MX (1)	MX354820B (pl)
NZ (1)	NZ629189A (pl)
PL (1)	PL2825542T3 (pl)
PT (1)	PT2825542T (pl)
RS (1)	RS55532B1 (pl)
SG (1)	SG11201405323YA (pl)
SI (1)	SI2825542T1 (pl)
SM (1)	SMT201700009B (pl)
WO (1)	WO2013138568A1 (pl)
ZA (1)	ZA201406390B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2825542T3 (pl) *	2012-03-16	2017-05-31	Vitae Pharmaceuticals, Inc.	Modulatory wątrobowego receptora x
DK2825541T3 (en) *	2012-03-16	2016-10-03	Vitae Pharmaceuticals Inc	LIVER-X-receptor modulators
AU2015204572B2 (en)	2014-01-10	2020-07-30	Inspirna, Inc.	LXR agonists and uses thereof
US20170231992A1 (en) *	2014-06-19	2017-08-17	Vitae Pharmaceuticals, Inc.	Compounds for use in treating acute coronary syndrome and related conditions
US10144715B2 (en)	2014-08-07	2018-12-04	Vitae Pharmaceuticals, Inc.	Piperazine derivatives as liver X receptor modulators
WO2017083216A1 (en) *	2015-11-12	2017-05-18	Merck Sharp & Dohme Corp.	Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use
AU2017207291B2 (en)	2016-01-11	2023-06-15	The Rockefeller University	Methods for the treatment of myeloid derived suppressor cells related disorders
CN109661238B (zh)	2016-07-27	2023-07-25	哈里斯制药公司	治疗红细胞疾病的治疗组合
WO2019104062A1 (en)	2017-11-21	2019-05-31	Rgenix, Inc.	Polymorphs and uses thereof
BR112020023001A2 (pt)	2018-05-15	2021-02-02	Alkahest, Inc.	tratamento de doença associada ao envelhecimento com moduladores da leucotrieno a4 hidrolase
JP2022523773A (ja) *	2019-02-28	2022-04-26	ザロックフェラーユニバーシティー	がんの予後及び治療におけるａｐｏｅ遺伝子型決定
EP3999055A1 (en)	2019-07-15	2022-05-25	Novartis AG	Methods for treating meibomian gland dysfunction with liver x receptor agonists
US11174220B2 (en)	2019-12-13	2021-11-16	Inspirna, Inc.	Metal salts and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4748247A (en)	1986-10-21	1988-05-31	American Home Products Corporation	2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
CA2074163A1 (en)	1990-01-22	1991-07-23	William Thomas Zimmerman	Herbicidal sulfonylureas
EP0572863A1 (de)	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
ATE290378T1 (de)	1993-12-23	2005-03-15	Lilly Co Eli	Proteinkinase c-inhibitoren
US5545636A (en)	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
WO1996012721A1 (en)	1994-10-20	1996-05-02	American Home Products Corporation	Indole derivatives useful as serotonergic agents
AU721130B2 (en)	1996-06-28	2000-06-22	Merck & Co., Inc.	Fibrinogen receptor antagonists
WO1998000401A1 (en)	1996-06-28	1998-01-08	Merck & Co., Inc.	Fibrinogen receptor antagonist prodrugs
US5854245A (en)	1996-06-28	1998-12-29	Merck & Co., Inc.	Fibrinogen receptor antagonists
JP2000514427A (ja)	1996-06-28	2000-10-31	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲンレセプター拮抗薬プロドラッグ
US6177440B1 (en)	1996-10-30	2001-01-23	Eli Lilly And Company	Substituted tricyclics
FR2761073B1 (fr)	1997-03-20	1999-04-23	Synthelabo	Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761070B1 (fr)	1997-03-20	1999-04-23	Synthelabo	Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de)	1998-01-22	1999-07-29	Bayer Ag	Mit tricyclischen Indolen substituierte Oxazolidinone
IL129484A0 (en)	1998-04-17	2000-02-29	Lilly Co Eli	Substituted tricyclics
DE60018274T2 (de)	1999-05-06	2005-08-04	Neurogen Corp., Branford	Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
US7037916B2 (en)	1999-07-15	2006-05-02	Pharmacopeia Drug Discovery, Inc.	Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it) *	1999-08-03	2002-09-09	Novuspharma Spa	Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en)	1999-10-22	2001-05-03	Eli Lilly And Company	Therapeutic compositions including protein kinase c inhibitors
ATE387199T1 (de)	2000-01-06	2008-03-15	Merck Frosst Canada Ltd	Neue substanzen und verbindungen als protease- inhibitoren
EP1325008B1 (en)	2000-07-31	2005-10-05	F. Hoffmann-La Roche Ag	Piperazine derivatives
HUP0303316A2 (hu)	2000-12-20	2004-01-28	Bristol-Myers Squibb Pharma Company	Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
GB0106177D0 (en)	2001-03-13	2001-05-02	Hoffmann La Roche	Piperazine derivatives
FR2829766A1 (fr)	2001-09-14	2003-03-21	Lipha	Derives d'oxamates comportant un heterocycle azote diversement substitue
NZ533649A (en)	2001-12-21	2006-01-27	King Pharmaceuticals Res & Dev	Tyrosyl derivatives and their use as P2X7 receptor modulators
US7919497B2 (en)	2002-08-02	2011-04-05	Nereus Pharmaceuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de)	2003-05-09	2005-01-20	Bayer Healthcare Ag	Heterocyclyl-substituierte Dihydrochinazoline
JP4734119B2 (ja)	2004-02-12	2011-07-27	田辺三菱製薬株式会社	インダゾール化合物及びその医薬用途
BRPI0509754A (pt)	2004-04-08	2007-10-16	Novartis Ag	inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante
RU2266906C1 (ru)	2004-04-29	2005-12-27	Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия")	Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it)	2004-04-30	2004-07-30	Ist Naz Stud Cura Dei Tumori	Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en)	2004-05-21	2005-12-01	Pfizer Products Inc.	Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
RU2007121768A (ru)	2004-12-15	2009-01-27	Ф. Хоффманн-Ля Рош Аг (Ch)	Би- и трициклически замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения болезни альцгеймера
WO2006072608A2 (en)	2005-01-03	2006-07-13	Universitá Degli Studi Di Siena	Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en)	2005-03-17	2010-09-07	Boehringer Ingelheim Pharmaceutical, Inc.	Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en)	2005-04-07	2006-10-12	Pfizer Inc.	Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
AU2006268724B2 (en)	2005-07-14	2011-06-02	F. Hoffmann-La Roche Ag	Indol-3-carbonyl-spiro-piperidine derivatives as V1A receptor antagonists
EP1926724A1 (en)	2005-09-21	2008-06-04	Nereus Pharmaceuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en)	2005-10-28	2007-05-02	Nikem Research S.R.L.	V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP4882127B2 (ja) *	2005-11-16	2012-02-22	株式会社ジェイテクト	位置調整式ステアリング装置
JP2007137810A (ja) *	2005-11-17	2007-06-07	Sankyo Co Ltd	インドール化合物を含有する医薬
BRPI0619597A2 (pt)	2005-12-09	2011-10-04	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade, de diabetes do tipo ii, e seus usos
US7351706B2 (en)	2006-01-05	2008-04-01	Hoffmann-La Roche Inc.	Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) *	2006-02-03	2010-09-03	Sanofi Aventis	Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru)	2006-04-12	2008-03-10	Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия"	Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en)	2006-11-03	2012-03-06	Nereus Pharmacuticals, Inc.	Analogs of dehydrophenylahistins and their therapeutic use
EP2139850B1 (en)	2007-04-09	2018-09-12	MethylGene Inc.	Inhibitors of histone deacetylase
CN101784541A (zh)	2007-06-25	2010-07-21	纽罗根公司	哌嗪基氧代烷基四氢-β-咔啉及相关类似物
US20100197657A1 (en)	2007-09-25	2010-08-05	Chang Ronald K	2-aryl or heteroaryl indole derivatives
CN101456863B (zh) *	2007-12-14	2012-04-25	华北制药集团新药研究开发有限责任公司	Lxr激动剂及其制备方法和用途
JP2011507901A (ja) *	2007-12-21	2011-03-10	ワイス・エルエルシー	ピラゾロ［１，５−ａ］ピリミジン化合物
CL2009000116A1 (es)	2008-01-22	2010-08-27	Takeda Pharmaceutical Compnany Ltd	Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable.
WO2009097515A2 (en)	2008-01-30	2009-08-06	Wyeth	[a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20100137320A1 (en)	2008-02-29	2010-06-03	Schering Corporation	Gamma secretase modulators
JP5767101B2 (ja)	2008-03-28	2015-08-19	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	キナーゼ阻害剤として活性な３，４−ジヒドロ−２ｈ−ピラジノ［１，２−ａ］インドール−１−オン誘導体、これらの調製方法、およびこれらを含む医薬組成物
TW201031665A (en)	2009-02-04	2010-09-01	Gruenenthal Gmbh	Substituted indole-compound
ES2462290T3 (es)	2009-06-08	2014-05-22	Grünenthal GmbH	Bencimidazoles, benzotiazoles y benzoxazoles sustituidos
WO2011005295A1 (en)	2009-06-24	2011-01-13	Arena Pharmaceuticals, Inc.	Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
CA2772525A1 (en)	2009-09-11	2011-03-17	Sunovion Pharmaceuticals Inc.	Histamine h3 inverse agonists and antagonists and methods of use thereof
JP5643332B2 (ja)	2009-12-07	2014-12-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
WO2011109237A2 (en)	2010-03-02	2011-09-09	Emory University	Uses of noscapine and derivatives in subjects diagnosed with fap
KR101302474B1 (ko) *	2012-02-20	2013-09-02	주식회사 케이씨씨	내충격성 및 불연성이 우수한 진공단열재용 봉지부재
PL2825542T3 (pl) *	2012-03-16	2017-05-31	Vitae Pharmaceuticals, Inc.	Modulatory wątrobowego receptora x
DK2825541T3 (en)	2012-03-16	2016-10-03	Vitae Pharmaceuticals Inc	LIVER-X-receptor modulators

2013
- 2013-03-14 PL PL13712103T patent/PL2825542T3/pl unknown
- 2013-03-14 BR BR112014022780A patent/BR112014022780A8/pt not_active Application Discontinuation
- 2013-03-14 AU AU2013232069A patent/AU2013232069B2/en not_active Ceased
- 2013-03-14 ME MEP-2016-289A patent/ME02660B/me unknown
- 2013-03-14 LT LTEP13712103.4T patent/LT2825542T/lt unknown
- 2013-03-14 PT PT137121034T patent/PT2825542T/pt unknown
- 2013-03-14 SI SI201330426A patent/SI2825542T1/sl unknown
- 2013-03-14 MX MX2014011104A patent/MX354820B/es active IP Right Grant
- 2013-03-14 WO PCT/US2013/031250 patent/WO2013138568A1/en active Application Filing
- 2013-03-14 US US14/385,671 patent/US9073931B2/en active Active
- 2013-03-14 NZ NZ629189A patent/NZ629189A/en not_active IP Right Cessation
- 2013-03-14 CN CN201380014301.3A patent/CN104203950B/zh not_active Expired - Fee Related
- 2013-03-14 SG SG11201405323YA patent/SG11201405323YA/en unknown
- 2013-03-14 JP JP2015500603A patent/JP6114815B2/ja not_active Expired - Fee Related
- 2013-03-14 ES ES13712103.4T patent/ES2607113T3/es active Active
- 2013-03-14 EP EP13712103.4A patent/EP2825542B1/en active Active
- 2013-03-14 DK DK13712103.4T patent/DK2825542T3/en active
- 2013-03-14 KR KR1020147028756A patent/KR102069913B1/ko active IP Right Grant
- 2013-03-14 HU HUE13712103A patent/HUE030785T2/en unknown
- 2013-03-14 EA EA201491610A patent/EA026431B1/ru unknown
- 2013-03-14 RS RS20161114A patent/RS55532B1/sr unknown
- 2013-03-14 CA CA2865639A patent/CA2865639C/en not_active Expired - Fee Related
2014
- 2014-08-26 IL IL234301A patent/IL234301A/en active IP Right Grant
- 2014-08-29 ZA ZA201406390A patent/ZA201406390B/en unknown
2015
- 2015-05-26 US US14/721,262 patent/US9416135B2/en active Active
- 2015-07-16 HK HK15106802.8A patent/HK1206332A1/xx not_active IP Right Cessation
2016
- 2016-07-07 US US15/204,422 patent/US9707232B2/en active Active
- 2016-12-12 HR HRP20161690TT patent/HRP20161690T1/hr unknown
- 2016-12-12 CY CY20161101280T patent/CY1118323T1/el unknown
2017
- 2017-01-10 SM SM201700009T patent/SMT201700009B/it unknown
- 2017-03-14 JP JP2017048433A patent/JP2017128589A/ja active Pending
- 2017-04-25 IL IL251897A patent/IL251897A0/en unknown
- 2017-06-09 US US15/618,297 patent/US20180117041A1/en not_active Abandoned
2018
- 2018-09-14 JP JP2018172261A patent/JP2019006813A/ja active Pending
2019
- 2019-05-21 US US16/418,339 patent/US20200138812A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RS55532B1 (sr)	2017-05-31
JP6114815B2 (ja)	2017-04-12
WO2013138568A8 (en)	2014-08-28
JP2019006813A (ja)	2019-01-17
US9707232B2 (en)	2017-07-18
EP2825542A1 (en)	2015-01-21
CN104203950B (zh)	2016-08-24
IL251897A0 (en)	2017-06-29
JP2015514061A (ja)	2015-05-18
HUE030785T2 (en)	2017-06-28
HK1206332A1 (en)	2016-01-08
CA2865639C (en)	2020-12-22
US20150336963A1 (en)	2015-11-26
ME02660B (me)	2017-06-20
SI2825542T1 (sl)	2017-01-31
AU2013232069B2 (en)	2017-07-13
CN104203950A (zh)	2014-12-10
EP2825542B1 (en)	2016-09-14
MX354820B (es)	2018-03-21
SMT201700009B (it)	2017-03-08
JP2017128589A (ja)	2017-07-27
IL234301A (en)	2017-09-28
US20180117041A1 (en)	2018-05-03
EA201491610A1 (ru)	2014-12-30
EA026431B1 (ru)	2017-04-28
DK2825542T3 (en)	2017-01-09
KR102069913B1 (ko)	2020-01-23
NZ629189A (en)	2016-08-26
KR20140135829A (ko)	2014-11-26
MX2014011104A (es)	2014-12-05
HRP20161690T1 (hr)	2017-02-24
AU2013232069A1 (en)	2014-09-18
ES2607113T3 (es)	2017-03-29
LT2825542T (lt)	2016-12-27
US20200138812A1 (en)	2020-05-07
US20170007603A1 (en)	2017-01-12
US9416135B2 (en)	2016-08-16
CY1118323T1 (el)	2017-06-28
SG11201405323YA (en)	2014-10-30
WO2013138568A1 (en)	2013-09-19
PT2825542T (pt)	2016-12-20
US9073931B2 (en)	2015-07-07
ZA201406390B (en)	2019-11-27
CA2865639A1 (en)	2013-09-19
BR112014022780A8 (pt)	2021-06-15
US20150065515A1 (en)	2015-03-05
BR112014022780A2 (pt)	2017-06-20

Publication	Publication Date	Title
IL251897A0 (en)	2017-06-29	X-receptor modulators of the liver
GB201213700D0 (en)	2012-09-12	Receptor antagnists II
PL2663550T4 (pl)	2017-07-31	Podstawione benzoazepiny jako modulatory receptora toll-podobnego
PL2663555T4 (pl)	2017-08-31	Podstawione benzoazepiny jako modulatory receptora toll-podobnego
HK1206333A1 (en)	2016-01-08	Liver receptor modulators
GB201004739D0 (en)	2010-05-05	Receptor modulators
HK1208867A1 (en)	2016-03-18	Indolecarbonitriles as selective androgen receptor modulators
HK1209744A1 (en)	2016-04-08	Novel selective androgen receptor modulators
IL235557A0 (en)	2015-02-01	Modulators of 17 gpr receptors
GB201223053D0 (en)	2013-02-06	Receptor
SI2820010T1 (sl)	2018-11-30	Derivati benzofuran-2-sulfonamida kot modulatorji kemokinskih receptorjev
EP2922539A4 (en)	2016-04-20	SUBSTITUTED ISOQUINOLINES USEFUL AS MODULATORS OF THE CRTH2 RECEPTOR
GB2501462B (en)	2016-12-28	Structural fixing
GB201202526D0 (en)	2012-03-28	Structural fixing
GB201219451D0 (en)	2012-12-12	Tiling